Navigation Links
PDL BioPharma Acquires Portfolio of Diabetes Royalty Rights and Milestones from Depomed
Date:10/21/2013

INCLINE VILLAGE, Nev., Oct. 21, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) announced today that it has acquired the rights to receive royalties and milestones payable on sales of Type 2 diabetes products licensed by Depomed (NASDAQ: DEPO) in exchange for a $240.5 million cash payment. PDL will receive all royalty and milestone payments due under the agreements until it has received payments equal to two times the cash payment made to Depomed, after which all payments received will be shared evenly between PDL and Depomed. 

(Logo: http://photos.prnewswire.com/prnh/20110822/SF55808LOGO)

The rights acquired include Depomed's royalty and milestone payments accruing from and after October 1, 2013: (a) from Santarus with respect to sales of Glumetza® (metformin HCL extended-release tablets) in the United States; (b) from Merck with respect to sales of Janumet® XR (sitagliptin and metformin HCL extended-release); (c) from Janssen Pharmaceutica with respect to potential future development milestones and sales of its investigational fixed-dose combination of Invokana® (canagliflozin) and extended-release metformin; (d) from Boehringer Ingelheim with respect to potential future development milestones and sales of the investigational fixed-dose combinations of drugs and extended-release metformin subject to Depomed's license agreement with Boehringer Ingelheim; and (e) from LG Life Sciences and Valeant Pharmaceuticals for sales of extended-release metformin in Korea and Canada, respectively.

The most recent American Diabetes Association, NIH and CDC estimates are that 8.3 percent of the US population
'/>"/>

SOURCE PDL BioPharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. PDL BioPharma Provides $60 Million in Financing to LENSAR
2. Global Biopharma Mergers & Acquisition and Deal Making Report 2013: Understanding the Latest Trends to Optimize Future Strategy
3. PDL BioPharma to Present at the 4th Annual Credit Suisse Small/Mid Cap Conference
4. PDL BioPharma Provides Third Quarter 2013 Revenue Guidance of $97 Million
5. Market Research Reports: Biologics, Biosimilars, Bioseparation Systems for Biopharmaceutical Markets
6. New HAE Drug Candidate from Dyax Produced by Laureate Biopharma
7. Morning Research: BioCryst Pharma Inc., Questcor Pharma Inc., PDL BioPharma Inc., and Amgen Inc.
8. Robbins Arroyo LLP Is Investigating the Directors and Officers of Navidea Biopharmaceuticals, Inc.
9. PDL BioPharma Announces Second Quarter 2013 Financial Results
10. Pre-Market Analysis: MannKind, Galena Biopharma, Ariad Pharma, and Novavax
11. Array BioPharma To Report Financial Results For The Fourth Quarter And Full Year Of Fiscal 2013 On August 7, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... , March 6, 2015 ... des cohortes de patients pouvant bénéficier de l,innovation ... des solutions d,enrichissement sémantique de contenu pour l,Entreprise, ... par UNICANCER, Groupe des Centres de lutte contre ... cadre de son projet ConSoRe (Continuum Soin-Recherche) conduit ...
(Date:3/5/2015)... JERUSALEM , March 5, 2015 ... a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing ... it has commenced an underwritten public offering of ... of its Ordinary Shares. All of the ADSs ... BioLineRx.  JMP Securities is acting ...
(Date:3/5/2015)... PharmaTech (Cayman) Inc. (NYSE: WX ), a ... the pharmaceutical, biotechnology, and medical device industries, with operations ... financial results for the fourth quarter and full year ... Net Revenues Increased 21.3% Year Over Year to $190.6 ... Year Over Year to $140.5 Million , Manufacturing ...
Breaking Medicine Technology:TEMIS et SWORD accompagnent UNICANCER pour accélérer la recherche par l'analyse sémantique des dossiers patients 2TEMIS et SWORD accompagnent UNICANCER pour accélérer la recherche par l'analyse sémantique des dossiers patients 3TEMIS et SWORD accompagnent UNICANCER pour accélérer la recherche par l'analyse sémantique des dossiers patients 4BioLineRx Announces Underwritten Public Offering of its American Depositary Shares 2BioLineRx Announces Underwritten Public Offering of its American Depositary Shares 3WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 2WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 3WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 4WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 5WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 6WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 7WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 8WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 9WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 10WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 11WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 12WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 13WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 14WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 15WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 16WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 17WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 18WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 19WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 20WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 21WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2014 Results 22
... USHIFU, LLC, a global leader in,non invasive high ... sponsorship of the Sonablate(R) International HIFU Registry,(SIHR), along ... and Takai,Hospital Supply Co., Ltd., (THS). The SIHR ... information about prostate cancer treatment using HIFU.,It was ...
... Benefits All Americans, WASHINGTON, July 9 In ... M.D., discussed the,safety and importance of the research programs ... as an absolute commitment to its patients,while expressing regret ... misused., "VA has an outstanding research program, and ...
Cached Medicine Technology:Sonablate(R) International HIFU Registry is the First Worldwide HIFU Clinical Registry for Prostate Cancer Treatments 2Sonablate(R) International HIFU Registry is the First Worldwide HIFU Clinical Registry for Prostate Cancer Treatments 3Secretary Reinforces VA's Commitment to Research Safety and Veteran Focus 2Secretary Reinforces VA's Commitment to Research Safety and Veteran Focus 3
(Date:3/6/2015)... (PRWEB) March 06, 2015 As the ... to be discussed, Ford & Associates Nationwide Legal Services, ... January 2015 filed lawsuit: Verduzco v. Daiichi Sankyo, Inc., ... of California. , “In light of a recently ... used Benicar to evaluate and explore the Mayo Clinic's ...
(Date:3/5/2015)... In 2014, the FDA approved 44 drugs, with ... scoring 4 drug approvals in the USA. The infectious ... drug products, followed by oncology therapy with 18% of ... CDK inhibitors keep on attracting large-cap pharmacos. Nivolumab and ... metastatic melanoma, and at present, they are being investigated ...
(Date:3/5/2015)... March 05, 2015 This week, ... in low-cost laminate flooring products, initiating widespread ... of eco-friendly building materials made primarily from bamboo, ... testing all their flooring products for volatile organic ... Benchmark International (BMH). Results from formaldehyde ...
(Date:3/5/2015)... NY (PRWEB) March 05, 2015 ... forward in a Pennsylvania mass tort litigation currently ... where a jury has begun hearing testimony in ... the atypical antipsychotic medication can cause gynecomastia, or ... case in question was filed on behalf of ...
(Date:3/5/2015)... RI (PRWEB) March 05, 2015 Rhode Island ... third year in a row to support the Providence College ... The donation covered the purchase of the ‘Think Pink’ uniforms, ... against Big East Conference opponent DePaul University at Alumni Hall/Mullaney ... to continue our support of the PC women’s basketball’s ‘Pink ...
Breaking Medicine News(10 mins):Health News:Mayo Clinic's Benicar Case Study Findings Prompts Commentary from Ford & Associates Nationwide Legal Services in Wake of a Recently Filed Benicar Lawsuit 2Health News:Mayo Clinic's Benicar Case Study Findings Prompts Commentary from Ford & Associates Nationwide Legal Services in Wake of a Recently Filed Benicar Lawsuit 3Health News:Mayo Clinic's Benicar Case Study Findings Prompts Commentary from Ford & Associates Nationwide Legal Services in Wake of a Recently Filed Benicar Lawsuit 4Health News:World Pharma Business and Large-Cap Companies Discussed by MP Advisors in In-demand Study Available at MarketPublishers.com 2Health News:World Pharma Business and Large-Cap Companies Discussed by MP Advisors in In-demand Study Available at MarketPublishers.com 3Health News:With Homeowners Concerned About Formaldehyde, Cali Bamboo Puts Safety Above Bottom Line 2Health News:Risperdal Lawsuits Move Forward in Pennsylvania, as Bernstein Liebhard LLP Comments on Start of Second Gynecomastia Trial 2Health News:Risperdal Lawsuits Move Forward in Pennsylvania, as Bernstein Liebhard LLP Comments on Start of Second Gynecomastia Trial 3Health News:RIMI Teams Up with PC Women’s Basketball in the Fight Against Breast Cancer 2
... WEDNESDAY, Dec. 8 (HealthDay News) -- Omega-3 fatty acids may ... fatty acid called DHA is used in the right ratio ... suggests. The researchers analyzed the results of some 15 ... commonly found in oily fish or in fish oil supplements ...
... a key role in the prevention of the painful ... new research from the University of Pennsylvania School of ... exercise limits a worsening of symptoms among women who ... of long-running advice that breast cancer survivors should avoid ...
... Eastern Virginia Medical School researchers have identified a ... people with Autism Spectrum Disorders (ASD), an aspect of ... of life. "Persons with Autism Spectrum Disorders ... unpleasant. They often don,t understand what other people are ...
... breakthrough? See what the experts have to say ... Perspectives on Psychological Science . Neuroimaging: ... Special Section on fMRI ( http://pps.sagepub.com/content/5/6/714.full ) ... widespread interest following the publication of Vul et ...
... News) -- One third of lesbian, gay, bisexual ... lifetime, but most of them are mentally strong, new ... of Illinois at Chicago conducted psychiatric interviews with 246 ... for major depression, post-traumatic stress disorder (PTSD), conduct disorder ...
... By Dennis Thompson HealthDay Reporter , WEDNESDAY, Dec. ... to sudden infant death syndrome a little more than two months ... The twins were born seven weeks early, on Feb. ... early arrival, said Glover, now 40 and living in Stone Mountain, ...
Cached Medicine News:Health News:Certain Formulations of Omega-3s Might Help With Depression 2Health News:Certain Formulations of Omega-3s Might Help With Depression 3Health News:Weightlifting slashes lymphedema risk after breast cancer treatment 2Health News:Weightlifting slashes lymphedema risk after breast cancer treatment 3Health News:Autism breakthrough: Researchers identify possible treatment for impaired sociability 2Health News:fMRI special section of Perspectives on Psychological Science 2Health News:fMRI special section of Perspectives on Psychological Science 3Health News:Researchers Assess Gay Youths' Mental Health 2Health News:Mother Talks of the Anger, Confusion and Grief of a SIDS Death 2Health News:Mother Talks of the Anger, Confusion and Grief of a SIDS Death 3
... Low Profile Ergonomic Design ... of neuroendoscopes offers rigid working ... steerable tip. The rigid scope ... approach to the target. The ...
... new biological material produced from ... implant, lyoplant can absorb in ... implant material with the recipient's ... minimizes suture channels, resulting in ...
The Bovie IDS Series are the latest electrosurgical generators with fully digital implementation....
Aaron 1250 is a multipurpose electrosurgical generator with monopolar and bi-polar functions....
Medicine Products: